Drug Profile
AV 1142742
Alternative Names: AV1142742; RhuDexLatest Information Update: 29 Nov 2022
Price :
$50
*
At a glance
- Originator Active Biotech
- Developer Active Biotech; Dr Falk Pharma; MediGene Ltd
- Class Anti-inflammatories; Antirheumatics; Small molecules
- Mechanism of Action B cell inhibitors; CD80 antigen inhibitors; T lymphocyte inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Primary biliary cirrhosis
- Discontinued Asthma; Autoimmune disorders; Rheumatoid arthritis
Most Recent Events
- 29 Nov 2022 Phase-II development is still ongoing for Primary biliary cirrhosis in Hungary, Slovakia, Italy, Poland, Belgium, Netherlands, United Kingdom and Germany (EudraCT2020-001961-34)
- 16 Nov 2020 Phase-II clinical trials in Primary biliary cirrhosis (In adults, In the elderly) in Slovakia, Italy, Poland, Belgium, Netherlands, United Kingdom and Germany after November 2020 (PO) (EudraCT2020-001961-34)
- 16 Nov 2020 Phase-II clinical trials in Primary biliary cirrhosis (In adults, In the elderly) in Hungary (PO) (EudraCT2020-001961-34)